Incannex Healthcare Inc
Research Incannex Healthcare Inc (IXHL) on Bullrun: market cap USD 44.87M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIXHL
- ExchangeNASDAQ
- CountryAustralia
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Market capUSD 44.87M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 48.41M
- Free cash flow-USD 2.46M
Valuation Snapshot
latest market cap is USD 44.87M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 86.00K | -USD 46.89M | -USD 12.52M | n/a | -1.35 | USD 15.04M | USD 163.00K | USD 13.39M |
| FY2024 | USD 12.00K | -USD 18.46M | -USD 16.12M | n/a | -1.15 | USD 5.86M | USD 4.10M | USD 11.22M |
| FY2023 | USD 0 | -USD 48.81M | -USD 11.07M | n/a | -3.32 | USD 22.12M | USD 470.00K | USD 20.83M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 44.87M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 128.60M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 37.70M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 73.64M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 170.65M | n/a | n/a | n/a |
About Incannex Healthcare Inc
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Incannex Healthcare Inc's market cap?
Incannex Healthcare Inc's market capitalization is USD 44.87M.
What does Incannex Healthcare Inc do?
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder.